Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. The Food and Drug Administration (FDA) has approved Blincyto ® (blinatumomab) for the treatment of adult and pediatric patients 1 month ...

Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia in Adolescent and Young Adults The following represents disclosure information provided by authors of this manuscript. All ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Radich is a ...

The TKI plus InO-based therapy for newly diagnosed Ph+ ALL successfully met the efficacy end point, achieving an 81% MR3+ rate within 2 courses with limited cycles of InO. The modified schema 2 ...

PHILADELPHIA (CBS) — A child's cancer diagnosis affects the entire family and those effects can be immense and in various forms. For the Taunk family, it means stress from the cancer and subsequent ...

Twelve years after Takeda's Iclusig (ponatinib) earned a restricted FDA approval to treat certain patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), the U.S.

While acute lymphoblastic leukemia (ALL) was still the primary cause of death, researchers saw a steady increase in 2-year survival from 27.8% to 54.8% even as patient age at the time of relapse after ...

ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and ...